| New nanomedicine research for prostate cancer
Bander, director of urological oncology research and the Bernard and Josephine Chaus Professor of Urological Oncology at Weill Cornell Medical College and a urologist at NewYork-Presbyterian Hospital/Weill Cornell Medical College. Several years ago, Dr. Bander's team developed the first antibodies to the external domain of prostate-specific membrane antigen (PSMA). PSMA is now widely considered the best prostate cancer cell surface target known. The lead antibody, J591, has been a focus of clinical trials at Weill Cornell, involving the Departments of Urology, Medicine (hematology-oncology) and Radiology (nuclear medicine), as well as at several other institutions. These trials have entered almost 300 patients and have demonstrated sensitive and specific cancer targeting in 97 percent of prostate cancer patients as well as anti-tumor activity.
Target-date retirement plans don't have to be tweaked
Q: My company offers target funds through our 401(k) plan, but I think the fund for my retirement date is too conservative for me. What do I do?
A: You have two options. You can invest in the fund that reflects the date you expect to retire, and then invest a higher percentage of your non-401(k) retirement savings in stocks and other more volatile -- and potentially more lucrative -- options. Or you can choose a target fund that's designed for someone younger than you.
Typically, companies offer a spectrum of target funds with retirement dates at five-year intervals. For example, your 401(k) might offer Vanguard's Target Retirement 2010, Target Retirement 2015, Target Retirement 2020, etc. If you plan to retire in 2025, you might choose the 2035 fund to get the more aggressive investment mix you're looking for.
Click here to view the list of recent Press Releases from LegalView
LegalView launched two new practice areas on the cholesterol drugs Vytorin and Zetia, which were recently cited in a study as providing no benefit on arterial plaque compared to the generic versions available. Zetia and Vytorin specifically, are more expensive than other versions of cholesterol drugs. - January 28, 2008 .
|
